21:38 , Aug 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Melding bispecifics and CAR T cells to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An anti-EGFRvIII CAR T cell engineered to secrete an anti-CD3, anti-EGFR bispecific antibody could treat glioblastoma. In a mouse model of EGFRvIII-positive or EGFRvIII-negative glioblastoma, the engineered cells decreased...
20:13 , Aug 15, 2019 |  BC Innovations  |  Translation in Brief

Marrying CARs and bispecifics for solid tumors

Companies are split on whether CAR T cells or bispecifics will be most efficacious in solid tumors, but one group thinks the best bet is to combine the approaches. A Harvard Medical School team unveiled...
00:05 , Aug 9, 2019 |  BC Innovations  |  Tools & Techniques

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...
20:28 , Jul 31, 2019 |  BC Extra  |  Company News

Apelian to lead new T cell company BlueSphere

With serial biotech executive David Apelian as CEO, University of Pittsburgh and UPMC spinout BlueSphere debuted Wednesday with plans to move its personalized T cell therapies into the clinic. Pitt professors Mark and Warren Shlomchik,...
23:54 , Jul 26, 2019 |  BioCentury  |  Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
00:48 , Jul 26, 2019 |  BC Innovations  |  Product Development

Institute for Protein Design's de novo revolution

Seattle's Institute for Protein Design is growing an army of spinouts that build proteins from the ground up. With applications ranging from multivalent vaccines and synthetic cytokines to precision cell therapies, these companies could put...
00:26 , Jul 20, 2019 |  BC Extra  |  Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials  The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) after...
00:38 , Jul 19, 2019 |  BC Innovations  |  Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

Two years in, GammaDelta says the $100 million Takeda option deal it signed months after launching gave the company a boost that would have been hard to come by any other way. Build-to-buy deal structures...
23:17 , Jul 12, 2019 |  BC Extra  |  Financial News

HitGen joins growing Shanghai IPO queue

The Shanghai Stock Exchange accepted an application from HitGen this week to list on its new science and technology innovation board. The small molecule discovery company proposed to sell at least 40 million shares and...
23:03 , Jul 11, 2019 |  BC Extra  |  Preclinical News

Elicio's cancer vaccine boosts CAR Ts for solid tumors

The MIT group behind cancer start-up Elicio reported that its technology for boosting immune responses to cancer vaccines can also prime CAR T cells to kill solid tumors. CAR T cell therapies have been approved...